Huyett William 4
4 · IRONWOOD PHARMACEUTICALS INC · Filed Apr 3, 2019
Insider Transaction Report
Form 4
Huyett William
Chief Operating Officer
Transactions
- Disposition to Issuer
Employee Stock Option (Right to Buy)
2019-04-01−242,579→ 16,171 totalExercise: $11.49Exp: 2029-01-29→ Class A Common Stock (242,579 underlying) - Disposition to Issuer
Class A Common Stock
2019-04-01−85,312→ 26,063 total - Award
Class A Common Stock
2019-04-01+1,483→ 27,546 total - Disposition to Issuer
Employee Stock Option (Right to Buy)
2019-04-01−232,032→ 105,468 totalExercise: $13.60Exp: 2028-01-02→ Class A Common Stock (232,032 underlying)
Footnotes (5)
- [F1]Represents the disposition of 85,312 restricted stock units in connection with the separation (the "Separation") of Cyclerion Therapeutics, Inc. ("Cyclerion") from Ironwood Pharmaceuticals, Inc. ("Ironwood") in exchange for restricted stock units representing the right to receive shares of Cyclerion Common Stock.
- [F2]In connection with the Separation, the reporting person received 1,483 restricted stock units as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation. This award vests as shares of Class A Common Stock on May 9, 2019.
- [F3]Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation. In connection with the Separation, the unvested portion of the Ironwood option award was replaced with options to purchase shares of Cyclerion Common Stock. The exercise price of the vested portion of the Ironwood option award has been adjusted, and the reporting person received additional options to purchase shares of Cyclerion Common Stock, to preserve the pre-Separation intrinsic value of the vested portion of the Ironwood option award.
- [F4]The remaining 105,468 shares are presently exercisable in full.
- [F5]The remaining 16,171 shares are presently exercisable in full.